NCI's Proposed IP Policy May Hinder Personalized Medicine, Stakeholders Say
August 25, 2010
NCI's Proposed IP Policy May Hinder Personalized Medicine, Stakeholders Say
NCI has outlined changes to its IP policies for collaborative research agreements that would essentially provide industry collaborators with first-option commercial licensing rights for IP arising from studies that make use of pharma companies' proprietary drugs, or samples from patients treated with those drugs.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Will Genentech Embrace PGx in Appeal of FDA Decision to Revoke Approval of Avastin in Breast Cancer?
December 22, 2010 / Pharmacogenomics Reporter - Despite PGx Leads, Avastin Access Debate Not Focused on Personalized Medicine Strategies
August 25, 2010 / Pharmacogenomics Reporter - FDA's ODAC Not Swayed by Genentech's Biomarker Strategy to ID Best Responders to Avastin
June 29, 2011 / Pharmacogenomics Reporter - Despite Passionate Patient Accounts, FDA Sees No Evidence of 'Super-Responders' in Avastin Trials
June 29, 2011 / Pharmacogenomics Reporter - Genentech, 23andMe Seek Participants for Study on Consumer-Driven GWAS Model
August 1, 2012 / Pharmacogenomics Reporter